Skip to main content

Maribavir Pregnancy and Breastfeeding Warnings

Medically reviewed by Last updated on Mar 30, 2022.

Maribavir is also known as: Livtencity

Maribavir Pregnancy Warnings

The manufacturer makes no recommendation regarding use during pregnancy.

US FDA pregnancy category: Not assigned.

Risk summary: No adequate human data available on use of this drug in pregnant women to inform a drug-related risk; in animal studies, embryofetal survival was reduced in rats, but not in rabbits.

Animal studies have revealed evidence of embryofetal harm. In rats, at oral doses of at least 100 mg/kg/day (exposures about half the human exposure at the recommended human dose [RHD]), decreased number of viable fetuses and increased early resorptions and postimplantation losses were observed; while intermittent reduced body weight gain was seen in pregnant rats at doses of at least 200 mg/kg/day, this drug had no effect on embryofetal growth or development at doses up to 400 mg/kg/day (exposures similar to those seen in humans at the RHD). In rabbits, at oral doses up to 100 mg/kg/day (exposures about half the human exposure at the RHD), no significant toxicological effects on embryofetal growth or development were observed. There are no controlled data in human pregnancy.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Maribavir Breastfeeding Warnings

Benefit should outweigh risk.

Excreted into human milk: Unknown
Excreted into animal milk: Unknown

-Developmental and health benefits of breastfeeding should be considered as well as the mother's clinical need for this drug.
-The effects in the nursing infant are unknown; potential side effects in the breastfed child due to this drug or the mother's underlying condition should be considered.

See references

References for pregnancy information

  1. "Product Information. Livtencity (maribavir)." Takeda Pharmaceuticals America (2021):

References for breastfeeding information

  1. "Product Information. Livtencity (maribavir)." Takeda Pharmaceuticals America (2021):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.